Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move: (TSXV: $KHRN.V) (NASDAQ: $NEPT) (NYSE: $ACB) (TSX: $ALEF.TO) (NASDAQ: $GWPH)
Delta, Kelowna, BC –November 11, 2019- (Investorideas.com Newswire) Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight from thought leaders and experts.
Listen to the podcast:
Read this in full at
Good afternoon and welcome to another episode of Investorideas.com "Potcast" featuring cannabis news, stocks to watch as well as insights from thought leaders and experts
In today’s podcast we look at a few early announcements.
Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) announced today that the Company will introduce the Aceso™ Hemp brand to the Latin America market, with initial sales beginning in Q4 2019 in Colombia. Aceso Hemp, which is part of the Dixie Brands family of products, produces a line of innovative balms for the growing hemp-based consumer wellness market, and is widely established in the US market. Aceso represents the first brand to enter the Latin America market under the Company's joint venture with Dixie Brands Inc. (CSE: DIXI.U).
Aceso Hemp is the next generation in hemp, pairing plant science with food science. Offering a growing line of indication-specific, hemp-derived supplements for promoting optimal health, Aceso Hemp was one of the first entrants in the category and brings a deep understanding of the industry's complex regulatory structure and expertise in the production of safe, effective and compliant products that can be sold across the United States. Aceso Hemp's scientists have studied, tested and perfected phyto-nutrient ratios that unlock the powers of hemp, resulting in sophisticated formulas that are easy for the body to absorb and activate.
With its market-leading knowledge of the Latin American market Khiron will initially prioritize two Aceso products for commercialization in the Colombian market. Aceso Alfa Balm and Aceso Sigma Balm blend essential oils and ingredients to soothe aching muscles and revitalize skin, and enhance their impact with broad-based hemp. Each product contains 56 mg of naturally occurring cannabinoids.
Alvaro Torres, Khiron CEO and Director, commented, "Khiron is one of very few cannabis companies with the cash reserves to continue to aggressively expand its business operations. Our strong balance sheet and proven operational team positions us to further take advantage of the tremendous market demand that we see for CBD consumer products in the LatAm region. The introduction of the Aceso brand, the first from our joint venture with Dixie Brands, positions us to build on the brands already wide adoption in the US and translate that through our establish retail network to consumers in Latin America."
The launch of Aceso into Colombia continues the Company's strategy to bring innovative CBD-based cosmeceutical and wellness products to the Latin American market. In 2018 the Company launched Kuida, a comprehensive line of skincare products which are now sold across Colombia, are set to launch in the US and have received approval for commercialization in the UK.
Michael McMahon, Dixie's General Manager of Latin America, added, "We are excited to see our joint venture with Khiron starting to yield the opportunities to introduce our products into the market. This is the tip of the iceberg, and as we continue to refine our products to meet the regulatory requirements in each country, we will be expanding into more countries and delving deeper into our product portfolio."
Neptune Wellness Solutions Inc. (NASDAQ: NEPT) (TSX: NEPT) announced that it has entered into a collaboration agreement with International Flavors & Fragrances Inc. (NYSE: IFF) to co-develop hemp-derived CBD products for the mass retail and health & wellness markets. App Connect Service, Inc. is also a party to the agreement to provide related branding strategies and promotional activities. In conjunction with the co-development partnership, Neptune will issue to warrants(1) to IFF.
Under this strategic product development partnership, IFF will leverage its intellectual property (IP) for taste, scent and nutrition to provide essential oils and product development resources. Neptune will leverage its proprietary cold ethanol extraction processes and formulation IP to deliver high quality, full- and broad-spectrum extracts for the development, manufacture and commercialization of hemp-derived products, infused with essential oils, for the cosmetics, personal care and home care markets.
The first products are expected to launch under Neptune's Forest Remedies brand at U.S. retailers in the first half of calendar 2020. The Initial launch will include a variety of topical products across the aromatherapy category, a market estimated at approximately $3 billion annually. Additional category launches should follow and the total SKU count could ultimately exceed 50 SKUs. Neptune will be responsible for the marketing and sale of the products. Neptune will record revenues from product sales and in turn will pay a royalty to each of IFF and App Connect associated with the sales of co-developed products(2).
"The agreement represents a significant event in the development of our global cannabis business, expanding our business model from primarily B2B to include a robust B2C business platform. IFF has an impressive track record, remarkable capabilities and global reach. This partnership will accelerate Neptune's vision and growth strategy to be the leading producer of hemp extracts ingredients and finished products for the global health & wellness and Consumer Packaged Goods industries. We are also now better positioned to leverage our management's experience building brands and relationships with key North American retailers," stated Michael Cammarata, CEO of Neptune.
"We are pleased to enter this strategic partnership and drive innovation that satisfies customers' demands for quality, sustainability and traceability," said Nicolas Mirzayantz, Divisional CEO, Scent at IFF. "The hemp-derived CBD products we are developing will target consumer preference towards natural health & wellness products."
The company also announced their financial and operating results for the three-month period ended September 30, 2019.
"We have a strong opportunity in the consumer market, and in recent months I have been focused on developing our B2B and B2C strategy for the U.S. market. According to most estimates, the U.S. hemp-derived CBD market is expected to exceed US$20 billion at retail in the next five years. This market size is roughly three to four times larger than the expected size of the Canadian cannabis market and represents our largest opportunity today. The collaboration agreement with IFF and the American Media partnership will help raise the awareness of our CBD brand, Forest Remedies™. We expect to introduce our first consumer products at retail locations and online with rollout commencing in the first half of CY2020," stated Michael Cammarata, CEO of Neptune.
Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB) announced the voting results from its Annual General Meeting of Shareholders, held in Edmonton, Alberta, on November 8, 2019.
The total number of shares represented by shareholders present in person and by proxy at the meeting was approximately 437.9 million, representing 42.6% of Aurora's issued and outstanding Common Shares.
All of the matters put forward before shareholders for consideration and approval as set out in the Company's Management Information Circular dated September 17, 2019, were approved by the requisite majority of votes cast at the Meeting. The details of the voting results for the election of directors are set out below:
Nominee
|
# Votes for
|
% Votes for
|
# Votes withheld
|
% Votes withheld
|
Ronald Funk
|
109,582,481
|
94.51%
|
6,359,922
|
5.49%
|
Shan Atkins
|
111,720,215
|
96.36%
|
4,222,186
|
3.64%
|
Norma Beauchamp
|
106,098,650
|
91.51%
|
9,843,752
|
8.49%
|
Jason Dyck
|
93,693,691
|
80.82%
|
22,231,335
|
19.18%
|
Adam Szweras
|
87,965,457
|
75.88%
|
27,959,570
|
24.12%
|
Terry Booth
|
97,756,441
|
84.33%
|
18,168,587
|
15.67%
|
Michael Singer
|
93,661,008
|
80.79%
|
22,264,019
|
19.21%
|
Steve Dobler
|
89,684,843
|
77.36%
|
26,240,184
|
22.64%
|
The shareholders also approved the: (i) appointment of KPMG LLP as auditors of the Company for the ensuing year; and (ii) non-binding advisory resolution on the Company's approach to executive compensation.
The Company has filed a report of voting results on all resolutions voted on at the Meeting on www.sedar.com.
Aleafia Health Inc. (TSX: ALEF) (OTC: ALEAF) reported that Aleafia Farms Inc., its wholly owned subsidiary, produced an inaugural Port Perry Outdoor Grow harvest yielding approximately 10,300 kg of dried flower. The yield figure is limited to dried flower, and excludes stems or other parts of the cannabis plant.
“Today, we can definitively say that Aleafia Health is among the lowest-cost producers, while realizing close to the highest revenue per gram sold among our peers as demonstrated in our upcoming third quarter financial results,” said Aleafia Health CEO Geoffrey Benic. “Low-cost production will only strengthen our core business model of growing, producing, selling and exporting high-quality, value-added cannabis health and wellness products globally.”
2019 OUTDOOR HARVEST HIGHLIGHTS
● 10,300 kg of dried flower harvested
● 1,000 kg per acre yield in Zone 1, which was planted in June 2019
● $0.08 cash cost per gram to harvest (unaudited)
● $0.10 all-in cash cost per gram to harvest, including facility capital costs (five-year amortization) (unaudited)
● Cannabinoid content (THC and CBD per gram) of harvested flower was strong, at levels near to the cannabinoid content in identical strains harvested indoor
● Quality assurance testing to date is successful, including for microbial content, pesticides and contaminants
“Our inaugural 2019 outdoor harvest was successful due to the commitment and capabilities of our team. I’d like to thank our on-site growers who navigated the challenging environment of starting the cultivation season late into the year and ultimately delivered an excellent harvest that we are measuring in tons,” said SVP of Production Lucas Escott.
Total yield and 2020 projected yield figures are approximations. Cash cost per gram to harvest includes all operating expenses such as labour, supplies, consumables, services and staff overhead. All-in cash cost per gram to harvest includes all operating expenses, along with capital costs including irrigation, security infrastructure and the newly constructed Drying Facility.
As previously announced, Health Canada amended Aleafia Farms’ license to add Zone 1 to the site on June 7, 2019, with planting completed by Aleafia Farms within one week. Health Canada amended Aleafia Farms’ license to add Zone 2 to the site on July 12, 2019, with planting completed by Aleafia Farms over the last two weeks of July. The six acre Zone 1, benefiting from an earlier planting date, yielded 1,000 kg per acre.
Based on the 2019 results, the Company estimates that it can produce 1,200 kg per acre for a total of 102,000 kg of dried flower in 2020 at its expanded 3.7 million sq. ft. (86 acre) outdoor site, at full capacity. The modest increase in the expected yield per acre for 2020 is due a number of factors which should improve the overall outdoor grow operation, including commencing cultivation several weeks earlier relative to 2019.
GW Pharmaceuticals plc (NASDAQ: GWPH) announced that two of its medicines, EPIDYOLEX (cannabidiol) oral solution and Sativex (nabiximols), have been recommended by the UK’s National Institute for Health and Care Excellence (NICE) to receive routine reimbursement from NHS England.
This represents the first-time any plant-derived cannabis-based medicine has been recommended by NICE for use on the NHS. Cannabidiol oral solution is recommended as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older. Nabiximols, reviewed as part of NICE’s evaluation of cannabis-based medicinal products (CBMPs), has been considered cost effective for the treatment of spasticity due to multiple sclerosis.
“This is a momentous occasion for UK patients and families who have waited for so many years for rigorously tested, evidenced and regulatory approved cannabis-based medicines to be reimbursed by the NHS,” said Chris Tovey, GW’s Chief Operating Officer. “This is proof that cannabis-based medicines can successfully go through extensive randomised placebo-controlled trials and a rigorous NICE evaluation process to reach patients. I am hugely proud of the entire GW team for achieving this milestone in the country where the company was founded and where both of these medicines were developed and are manufactured.”
Commenting on the NICE recommendation for cannabidiol oral solution, Dr Rhys Thomas, Consultant Neurologist at the Royal Victoria Hospital in Newcastle, said: “This is a significant moment for adults and children with the most difficult to treat epilepsies. NICE’s recommendation of cannabidiol oral solution follows a period of great anticipation and enthusiasm for patients and their clinicians. The European Medicines Agency (EMA) licence and availability through the NHS is welcome as we badly need additional effective treatments for Dravet and Lennox Gastaut syndromes.”
“We welcome the addition of cannabidiol oral solution as a new medicine to add to the Dravet syndrome treatment armamentarium. Dravet syndrome is a devastating condition and having a new treatment option offers potential new hope to patients and their families searching for better seizure control,” said Galia Wilson, Chair, Dravet Syndrome UK. “Many families come to us asking about the potential of cannabis-based medicines, particularly cannabidiol (CBD), and we are thrilled that one is now available on the NHS.”
When added to other anti-epileptic therapies, GW’s cannabidiol oral solution significantly reduced the frequency of seizures in patients with LGS and Dravet syndrome. The most common adverse reactions that occurred in patients treated with the medicine were somnolence, decreased appetite, diarrhoea, pyrexia, fatigue and vomiting. GW’s development programme represents the only well-controlled clinical evaluation of a cannabinoid medication for patients with refractory epilepsy.
GW’s cannabidiol oral solution was approved by the EMA and received marketing authorisation in September 2019 under the trade name EPIDYOLEX as an adjunctive therapy for seizures associated with LGS or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older. Following this approval, GW has been working with the relevant bodies in the UK, Germany, Spain, France and Italy to secure reimbursement ahead of the anticipated launch of the medicine in these countries.
The inclusion of nabiximols in NICE guidelines comes as part of the comprehensive evaluation of the clinical and cost-effectiveness of CBMPs. Nabiximols has been approved by medicines regulators in more than 25 countries around the world. Nabiximols was approved in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA) in 2010 and is marketed in the UK by GW’s commercial partner, Bayer.
Investor ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment
Investorideas.com podcasts are also available on iTunes, Spotify, Google Play Music, Stitcher, Spreaker, YouTube via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Cannabis Social Media
Contact Investorideas.com
800-665-0411
